MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme
Metrics: PDF 2028 views | HTML 1647 views | ?
Kristina H. Knubel1, Ben M. Pernu1, Alexandra Sufit1, Sarah Nelson1, Angela M. Pierce1, Amy K. Keating1
1 Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
Amy K Keating, email:
Keywords: MerTK, Axl, glioma, Foretinib, intracranial model
Received: January 16, 2014 Accepted: March 10, 2014 Published: March 12, 2014
Glioblastoma is an aggressive tumor that occurs in both adult and pediatric patients and is known for its invasive quality and high rate of recurrence. Current therapies for glioblastoma result in high morbidity and dismal outcomes. The TAM subfamily of receptor tyrosine kinases includes Tyro3, Axl, and MerTK. Axl and MerTK exhibit little to no expression in normal brain but are highly expressed in glioblastoma and contribute to the critical malignant phenotypes of survival, chemosensitivity and migration. We have found that Foretinib, a RTK inhibitor currently in clinical trial, inhibited phosphorylation of TAM receptors, with highest efficacy against MerTK, and blocked downstream activation of Akt and Erk in adult and pediatric glioblastoma cell lines, findings that are previously unreported. Survival, proliferation, migration, and collagen invasion were hindered in vitro. Foretinib treatment in vivo abolished MerTK phosphorylation and reduced tumor growth 3-4 fold in a subcutaneous mouse model. MerTK targeted shRNA completely prevented intracranial and subcutaneous glioma growth further delineating the impact of MerTK inhibition on glioblastoma. Our findings provide additional target validation for MerTK inhibition in glioblastoma and demonstrate that robust MerTK inhibition can be achieved with the multi-kinase inhibitor Foretinib as an innovative and translational therapeutic approach to glioblastoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.